Differential effect of interventions in patients with prediabetes stratified by a machine learning‐based diabetes progression prediction model

糖尿病前期 医学 吡格列酮 内科学 糖尿病 人口 曲线下面积 接收机工作特性 心理干预 空腹血糖受损 2型糖尿病 糖耐量受损 内分泌学 环境卫生 精神科
作者
Xiantong Zou,Yingying Luo,Qi Huang,Zhanxing Zhu,Yufeng Li,Xiuying Zhang,Xianghai Zhou,Linong Ji
出处
期刊:Diabetes, Obesity and Metabolism [Wiley]
卷期号:26 (1): 97-107 被引量:16
标识
DOI:10.1111/dom.15291
摘要

AIM: To investigate whether stratifying participants with prediabetes according to their diabetes progression risks (PR) could affect their responses to interventions. METHODS: We developed a machine learning-based model to predict the 1-year diabetes PR (ML-PR) with the least predictors. The model was developed and internally validated in participants with prediabetes in the Pinggu Study (a prospective population-based survey in suburban Beijing; n = 622). Patients from the Beijing Prediabetes Reversion Program cohort (a multicentre randomized control trial to evaluate the efficacy of lifestyle and/or pioglitazone on prediabetes reversion; n = 1936) were stratified to low-, medium- and high-risk groups using ML-PR. Different effect of four interventions within subgroups on prediabetes reversal and diabetes progression was assessed. RESULTS: Using least predictors including fasting plasma glucose, 2-h postprandial glucose after 75 g glucose administration, glycated haemoglobin, high-density lipoprotein cholesterol and triglycerides, and the ML algorithm XGBoost, ML-PR successfully predicted the 1-year progression of participants with prediabetes in the Pinggu study [internal area under the curve of the receiver operating characteristic curve 0.80 (0.72-0.89)] and Beijing Prediabetes Reversion Program [external area under the curve of the receiver operating characteristic curve 0.80 (0.74-0.86)]. In the high-risk group pioglitazone plus intensive lifestyle therapy significantly reduced diabetes progression by about 50% at year l and the end of the trial in the high-risk group compared with conventional lifestyle therapy with placebo. In the medium- or low-risk group, intensified lifestyle therapy, pioglitazone or their combination did not show any benefit on diabetes progression and prediabetes reversion. CONCLUSIONS: This study suggests personalized treatment for prediabetes according to their PR is necessary. ML-PR model with simple clinical variables may facilitate personal treatment strategies in participants with prediabetes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaoze完成签到 ,获得积分10
3秒前
WL完成签到 ,获得积分10
5秒前
5秒前
6秒前
8秒前
9秒前
梁白开完成签到,获得积分10
16秒前
菲菲完成签到,获得积分10
17秒前
jin完成签到,获得积分10
18秒前
随风沙ZYX完成签到 ,获得积分10
19秒前
阿明完成签到 ,获得积分10
19秒前
lambs13完成签到,获得积分10
20秒前
clxgene完成签到,获得积分10
21秒前
李爱国应助Wang采纳,获得10
23秒前
Criminology34应助许丫丫采纳,获得10
26秒前
share完成签到 ,获得积分10
32秒前
csg888888完成签到,获得积分10
32秒前
zzhui完成签到,获得积分10
34秒前
在水一方应助Roger采纳,获得10
39秒前
纯真冷安完成签到,获得积分10
39秒前
许丫丫完成签到,获得积分10
40秒前
铜豌豆完成签到 ,获得积分10
41秒前
41秒前
Haiverxin应助Rocky采纳,获得30
41秒前
lifeup完成签到 ,获得积分10
46秒前
47秒前
47秒前
史萌发布了新的文献求助10
48秒前
CC完成签到,获得积分10
49秒前
学术霸王完成签到,获得积分10
49秒前
打打应助晓淘采纳,获得10
49秒前
科研小白完成签到 ,获得积分10
51秒前
CC发布了新的文献求助10
52秒前
学术文献互助应助shirley采纳,获得100
57秒前
puritan完成签到 ,获得积分10
57秒前
李健的小迷弟应助CC采纳,获得10
1分钟前
刘德华完成签到 ,获得积分10
1分钟前
兰花二狗他爹完成签到,获得积分10
1分钟前
1分钟前
xiaojunsong完成签到 ,获得积分10
1分钟前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
Organic Reactions, Volume 116 1000
Current concepts in cutaneous toxicity : proceedings of the Fourth Conference on Cutaneous Toxicity, Washington, D.C., May 9-11, 1979 1000
ズームレンズの光学設計に関する研究 800
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7275307
求助须知:如何正确求助?哪些是违规求助? 8896424
关于积分的说明 18808039
捐赠科研通 6948208
什么是DOI,文献DOI怎么找? 3205748
关于科研通互助平台的介绍 2377289
邀请新用户注册赠送积分活动 2180565